Ahead of World Neglected Tropical Disease (NTD) Day 30 January, MSF demands improved global response for NTDs, including increased investment.

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

MSF authors describe medical activities for people for snakebite, including the importance of offering antivenom free of charge, though costly for MSF.

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

MSF publicly announced its first Clinical Trial Transparency Policy (CTTP). The CTTP outlines MSF’s commitment to the open sharing of information and costs on clinical trials.

A MSF report released today finds that two newer TB drugs – bedaquiline and delamanid – going off patent in 2023 presents a critical opportunity to increase access to shorter, safer and better treatment for people with drug-resistant ...

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

MSF reiterates that the price of a full DR-TB treatment course should be no more than US$500 per person.

Due to the high number of countries currently experiencing cholera outbreaks and a shortage of oral cholera vaccine, the International Coordinating Group (ICG) announced today that it will temporarily suspend the standard two-dose ...

On 5 October 2022, the World Health Organization (WHO) announced that South Africa’s vaccine regulatory system reached functional maturity (maturity level three [ML3]), recognising “that South Africa has a well-functioning and ...

Delays in supply of the critical GeneXpert TB test are unacceptable. Now more than ever, we need a doubling down on urgent actions to help countries scale up lifesaving TB testing.

MSF calls for full production capability in Aspen and Serum Institute of India fill and finish agreement for four vaccines

At 2022 International AIDS Conference, MSF calls for increased access to long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP).